Roche launches DISCOVERY 5-Plex procedure for cancer research applications
Fully automated fluorescent multiplex procedure enables researchers to investigate up to five biomarkers on one tissue slide
Tucson, AZ, November 21, 2016– Roche (SIX: RO, ROG; OTCQX:RHHBY) today announced the launch of its DISCOVERY 5-Plex procedure and reagents¹ for immunohistochemistry (IHC) research applications. This is the first pre-optimized, fully automated multiplex procedure available on the VENTANA DISCOVERY ULTRA² instrument.
Scientists globally are faced with the growing need to extract more information from limited tissue samples. DISCOVERY 5-Plex procedure allows researchers to investigate up to five biomarkers on a single slide, preserving tissue and maximizing data. The procedure provides researchers with a pre-optimized workflow that simplifies the staining process. The ready-to-use detection reagents provide crisp, specific signals and distinct information about protein co-expression patterns.
“To better investigate the complexities of cancer biology and possible treatment strategies, it is increasingly important to detect multiple biomarkers on a single slide,” said Ann Costello, Head of Roche Tissue Diagnostics. “The launch of the innovative DISCOVERY 5-Plex procedure advances automation in multiplexing technology, which is expected to play a critical role in cancer research in the future.”
As part of the DISCOVERY 5-Plex procedure launch, four new fluorescent kits used for this procedure will be commercially available³ – DISCOVERY FAM Kit, DISCOVERY Rhodamine 6G Kit, DISCOVERY Red 610 Kit and DISCOVERY DCC Kit.
¹Research Use Only. Not for use in diagnostic procedure.
³Availability outside the US is expected two months following this news release. Please inquire with your local country for availability.
About DISCOVERY products
The DISCOVERY product line is the research use only (RUO) portfolio of instruments and reagents developed by Roche Tissue Diagnostics for research in immunohistochemistry (IHC) and in situ hybridization (ISH). Included in the product line are the DISCOVERY ULTRA research instrument to fully automate single or multiplex IHC and ISH applications and a growing line of unique, ready-to-use reagents for full automation that are designed to meet the needs of the research community.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices.
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
Lung tissue at 40x magnification using
the DISCOVERY 5-Plex procedure